In rare move, FDA reverses course on drug developed by CEO with ties to Trump
In a rare reversal, the FDA has given Amicus Therapeutics the OK to submit its drug for approval, withdrawing a request that it do another clinical trial.
The Food and Drug Administration has changed its tune on an experimental drug for a deadly rare disease, withdrawing a request that the company developing it run another clinical trial. The unusual move comes after President Trump met with the company’s CEO — and promised to speed up what he called a “slow and burdensome” process for drug approvals.
Amicus Therapeutics, a New Jersey
